Answers are grounded in this paper and cite their sources.
Background Advanced chronic kidney disease (CKD) is often considered a contraindication to left ventricular assist device (LVAD) implantation, yet limited data exist on outcomes in the era of the HeartMate 3 device. Methods We retrospectively reviewed 193 patients who underwent HeartMate 3 LVAD implantation at a tertiary care academic medical center between July 2016 and July 2023. Patients were stratified by preoperative estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² (control, n = 154) vs <30 (advanced kidney disease, n = 39). Outcomes included survival and the need for renal replacement therapy (RRT). Results At 30 days post-implantation, survival was lower in advanced kidney disease patients compared with controls (84.6% vs 94.2%, p = 0.04). However, survival at 1 year (79.5% vs 79.9%, p = 0.87) and 2 years (73.9% vs 68.7%, p = 0.60) did not differ significantly. Post-implantation RRT was required in 30.3% of advanced kidney disease patients and 18.2% of controls ( p = 0.18). Conclusions Although early postoperative mortality is higher, patients with advanced CKD undergoing HeartMate 3 LVAD implantation achieve comparable 1- and 2-year survival to controls. These findings suggest LVAD implantation may be a reasonable option in carefully selected patients with advanced kidney disease.
No takes yet. Share an insight, caveat, or question.
French et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: